Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors
Globe Newswire•10/11/2026•11:05 ET
0
Key Highlights
- ➤TRYNGOLZA Q3 sales $9 million, missing commercial expectations
- ➤TRYNGOLZA full-year sales guidance cut to $50 million from $100 - $110 million
- ➤Ionis kept total company 2026 revenue guidance unchanged
- ➤Ionis (IONS) shares plunged $8.42 to $31.00, down 21.4%
NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).
Ionis is a commercial and clinical-stage drug company. IONS’ leading approved drug is TRYNGOLZA. The FDA approved TRYNGOLZA in December 2024 for patients with Familial Chylomicronemia Syndrome. On June 24, 2026, the FDA approved TRYNGOLZA as an adjunct to diet to lower someone’s triglycerides in adults with hypertriglyceridemia (sHTG).
Get started
Create a free account to read the full story.